[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361761-105":59,"doc-detail-361761-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","identification-of-68-hla-a24-and-a2-restricted-cytotoxic-t-lymphocyte-inducing-peptides-derived-from-10-common-cancer-specific-antigens","Identification of 68 HLA-A24 and -A2-restricted cytotoxic T lymphocyte-inducing peptides derived from 10 common cancer-specific antigens","","Targeting cancer antigens expressed on cancer cells is essential for cancer-specific immunotherapy. Immunohistochemistry was used to assess solid tumor specimens, extending prior work to include ROBO1, AFP, TGFBI, EphB4, CLDN1, and LAT1 alongside GPC3, HSP105α, FOXM1, and SPARC, showing these 10 common antigens cover most solid cancers. In silico screening predicted 72 and 73 HLA-A24 and HLA-A2 binding peptides from full-length antigen sequences, then HLA transgenic mice were immunized with peptide cocktails plus poly I:CLC three times weekly. Sixty-eight peptide sequences with stronger CTL induction than reference GPC3 peptides were identified, and cocktail peptide vaccines in tumor models demonstrated favorable safety and efficacy for clinical application.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/identification-of-68-hla-a24-and-a2-restricted-cytotoxic-t-lymphocyte-inducing-peptides-derived-from-10-common-cancer-specific-antigens/361761/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/identification-of-68-hla-a24-and-a2-restricted-cytotoxic-t-lymphocyte-inducing-peptides-derived-from-10-common-cancer-specific-antigens/361761.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were the antigen targets selected for peptide discovery?","Question",{"text":112,"@type":113},"The study used immunohistochemical analysis of solid cancer specimens and expanded previously studied antigens by adding ROBO1, AFP, TGFBI, EphB4, CLDN1, and LAT1 to GPC3, HSP105α, FOXM1, and SPARC, identifying 10 common cancer antigens that cover most solid cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What method was used to identify peptides restricted to HLA-A24 and HLA-A2?",{"text":117,"@type":113},"Peptides were predicted in silico to bind HLA-A24 and HLA-A2 using full-length amino acid sequences of the 10 antigens, followed by immunization of HLA transgenic mice with synthesized peptide cocktails plus poly I:CLC three times weekly.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the key outcome regarding the number and activity of identified peptides?",{"text":121,"@type":113},"A total of 68 peptide sequences (30 for HLA-A24 and 38 for HLA-A2) were identified that induced cytotoxic T lymphocytes more effectively than the GPC3 peptides used in clinical trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361761,1790443204,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Neoplasia 61 (2025) 101135  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>Identification of 68 HLA-A24 and -A2-restricted cytotoxic T lymphocyte-inducing peptides derived from 10 common cancer-specific antigens frequently expressed in various solid cancers |  |  | |\n| --- | --- | --- | --- |\n| Hiroki Kinoshita a,b, Kazumasa Takenouchib, Nobuo Tsukamoto b , Kazunobu Ohnukib, Toshihiro Suzuki b , Tetsuya Nakatsura b,* \u003Cbr>a Graduate School of Biological Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan\u003Cbr>b Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Common cancer antigen Cancer-specific antigen Cytotoxic T lymphocyte (CTL)\u003Cbr>Peptide vaccine mRNA vaccine HLA-A24\u003Cbr>HLA-A2 |  | Targeting cancer antigens expressed in cancer cells is necessary to develop cancer-specific immunotherapy. We have performed immunohistochemical analysis of various solid cancer specimens, adding ROBO1, AFP, TGFBI, EphB4, CLDN1, and LAT1 to the previously studied glypican-3 (GPC3), HSP105α, FOXM1, and SPARC, and found that these 10 common cancer antigens are sufficient to cover most solid cancers. These antigens were frequently expressed in various solid cancers but shown to be rarely ex-pressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. In this study, we predicted 72 and 73 peptides that bind to HLA-A24 and -A2 in silico from the full-length amino acid sequences of these 10 common cancer antigens and immunized each HLA transgenic mouse with a cocktail of synthesized peptides together with the poly I:CLC three times weekly to analyze the antigen-specific immune response. As a result, 68 peptide sequences (30 and 38, respectively) were identified that had higher cytotoxic T lymphocyte (CTL) induction ability than GPC3 298-306 and GPC3 144-152 used in the clinical trials. Furthermore, experiments with cocktail peptide vaccines using mouse models expressing subcutaneous tumors of each antigen showed promising results in terms of safety and efficacy. These peptides identified in this study, derived from 10 common cancer antigens covering all solid cancers, are expected to be clinically applicable as cocktail peptide vaccines. |  |\n\nIntroduction  \nClinical trials using glypican-3 (GPC3)-derived peptides have confirmed the safety and immunological efficacy of the vaccine, mainly in hepatocellular carcinoma (HCC), hepatoblastoma, etc [1–8]. In clinical trials, peptide-specific CTL reactions have been demonstrated in the peripheral blood of 80 % of patients treated and at the cancer site in some patients. Although the frequency was low even in advanced cancer, we have certainly experienced several successful cases, and have demonstrated the possibility that it can suppress recurrence after surgery for HCC that expresses GPC3 and contribute to long-term survival.  \nOn the other hand, we have experienced several patients whose HCC did not express GPC3 recurred despite the detection of many peptide-specific CTLs in the blood after HCC surgery. Thus, although GPC3 is highly expressed in many HCCs, the expression of the antigen in cancer cells is not uniform, making it difficult to prevent HCC recurrence with a single GPC3 peptide vaccine. It is also clear that a single peptide vaccine for GPC3 is insufficient to prevent the recurrence of HCC. As a notable result, seven children with refractory childhood cancer, including five with refractory hepatoblastoma who had repeated relapses and remissions, all survived more than 10 years without relapse using only the GPC3 peptide vaccine. Thus, although the GPC3 peptide  \nAbbreviations: AFP, alpha-fetopro","cbCaicTd9YUHG3NC","https://ap.wps.com/l/cbCaicTd9YUHG3NC","pdf",26915053,14,"English","# Introduction\n## Clinical experience with GPC3-derived peptide vaccines\n## Rationale for multi-antigen cocktail vaccines","[{\"question\":\"How were the antigen targets selected for peptide discovery?\",\"answer\":\"The study used immunohistochemical analysis of solid cancer specimens and expanded previously studied antigens by adding ROBO1, AFP, TGFBI, EphB4, CLDN1, and LAT1 to GPC3, HSP105α, FOXM1, and SPARC, identifying 10 common cancer antigens that cover most solid cancers.\"},{\"question\":\"What method was used to identify peptides restricted to HLA-A24 and HLA-A2?\",\"answer\":\"Peptides were predicted in silico to bind HLA-A24 and HLA-A2 using full-length amino acid sequences of the 10 antigens, followed by immunization of HLA transgenic mice with synthesized peptide cocktails plus poly I:CLC three times weekly.\"},{\"question\":\"What was the key outcome regarding the number and activity of identified peptides?\",\"answer\":\"A total of 68 peptide sequences (30 for HLA-A24 and 38 for HLA-A2) were identified that induced cytotoxic T lymphocytes more effectively than the GPC3 peptides used in clinical trials.\"}]","Identification of 68 HLA-A24 and -A2-restricted cytotoxic T lymphocyte-inducing peptides derived from 10 common cancer-specific antigens | PDF",1790145534,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/450b83b960d6972d5cf751899efbbd76.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7260eddf2eb390716fcc141b8bf29b96.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41d3be60e7ec791ae20d0f881670c7fc.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70b122c6dc61ef351fd5274bb5ca5478.webp",980,1306]